Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Provided By GlobeNewswire
Last update: Dec 4, 2025
Successful interim analysis triggered early stop for efficacy
Topline study results to be shared at the American Epilepsy Society Annual Meeting
on December 6, 2025
270.98
+22.99 (+9.27%)
Find more stocks in the Stock Screener
PRAX Latest News and Analysis
